argenx

argenx is a Ghent, Belgium-based biopharmaceutical company that is relevant as a corporate strategic investor for life sciences startups. Its investment signal is tied to later-stage venture participation in the United States, with fit for biotechnology and pharmaceutical therapeutics aligned with immunology drug discovery and development. The company develops therapies for severe autoimmune diseases and has marketed products including VYVGART and VYVGART Hytrulo, making it most relevant for founders seeking strategic capital or partnership around differentiated therapeutics.